Multiple Sclerosis Research Studies PDF Print E-mail

Dr. Yelena Usmanova is involved in numerous research trials related to advances in the treatment of Multiple Sclerosis.

WA21092 (“Opera”)

Study Overview

A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif ®) In Patients with Relapsing Multiple Sclerosis

Study Duration--96 Weeks

Phase-III

Enrollment Closed

Principle Investigator

Gary Birnbaum, MD       

Sponsor

F.Hoffmann-La Roche Ltd

OS440-3002 (“Osmotica”)

Study Overview

A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy of Increasing Doses of Arbaclofen Extended Release Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients with Multiple Sclerosis

Study Duration--21 Weeks

Phase-III

Enrollment Closed

Principle Investigator

Gary Birnbaum, MD

Sponsor

Osmotica Pharmaceutical Corp

LPS13567 (“TeriPro”)

Study Overview

A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients

Study Duration--49 Weeks

Phase-IV

Principle Investigator

Gary Birnbaum, MD

Sponsor

Sanofi

Research Contact

If interested please contact Neha Goyal (Clinical Research Coordinator) @ 763-302-4072.

109MS404 (“Respond”)

Study Overview

A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient Reported Outcomes of Oral Tecfidera™ (dimethyl fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate.

Study Duration—12 Months

Phase-IV

Principle Investigator

Gary Birnbaum, MD

Sponsor

Biogen Idec

Research Contact

If interested please contact Neha Goyal (Clinical Research Coordinator) @ 763-302-4072.

 

The EPOC Study – DUS01 (Closed)

What is the EPOC study?

EPOC is a 6-month clinical research study involving patients who are currently being treated for relapsing forms of MS. The main purpose of this study is to learn about patient satisfaction, safety and tolerability with Fingolimod compared to other approved MS drugs. About 1,000 patients with relapsing forms of MS will join this study at about 175 medical centers in the United States.

What happens during the study?

During this 6-month study, you will receive treatment of either the study drug (Fingolimod) or another drug that is currently being used to treat patients diagnosed with relapsing forms of MS. Whether you receive the study drug or a currently available therapy is decided by chance (like tossing a coin). Three out of four patients will receive the study drug.

Study Appointments

After the study screening, you will be scheduled for five office visits during the 24-week (6-month) study. Most visits will take about an hour. Some visits may require extra time. If you are chosen to receive Fingolimod, you will need to stay in the study doctor’s office for 7-8 hours on the second visit, which is when you take your first dose.

Principal Investigator

Jonathan Calkwood, M.D.

Clinical Trial Sponsor

Novartis
Follow this link to find other location listings and/or take an online screening questionnaire.

109MS201 (Closed)

An Open-Label, Multicenter Study in Subjects with Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)

Purpose of study

To evaluate the safety and determine if the investigational drug BG0012, when taken in combination with another prescribed MS therapy, improves MS symptoms. You may be eligible for this study if you have relapsing-remitting MS, have been on an MS therapy for at least one year and still have symptoms.

Principal Investigator

Jonathan Calkwood, M.D.

Clinical Trial Sponsor

Biogen

 
Clinic Locations

GOLDEN VALLEY / MAIN OFFICE
4225 Golden Valley Road, Golden Valley, MN 55422
(763) 588-0661

BURNSVILLE
Oak Ridge East Professional Building
675 E. Nicollet Boulevard, Suite 100, Burnsville, MN 55337
(952) 435-8516 (Neurology services)
(952) 898-5000 (Rehab services)

COON RAPIDS
3833 Coon Rapids Blvd., Suite 100, Coon Rapids, MN 55433
(763) 427-8320

EDINA
Southdale Place
3400 West 66th St, Suite 150, Edina, MN 55435
(952) 920-7200 (Neurology services)
(952) 920-8088 (Rehab services)

MAPLE GROVE
North Memorial Medical Office
9825 Hospital Drive, Suite 103, Maple Grove, MN 55369
(763) 302-4114

OUTREACH LOCATIONS
Twin Cities Metro, Greater Minnesota & Western Wisconsin